Research on the relationship of serum sclerostin level and bone density in maintenance hemodialysis patients / 中国综合临床

ABSTRACT

Objective To investigate whether serum sclerostin level is an indicator of the prognosis in patients with maintenance hemodialysis(MHD).Methods The clinical data of MHD patients treated in Yan′an University Affiliated Hospital in recent 3 years were collected to record their basic information and routine blood biochemical indexes.Serum Sclerostin levels were measured by ELISA calcaneus,while bone mineral density(BMD)was measured by quantitative ultrasound(QUS);correlation analysis was applied to screen the indicators affecting BMD.Logiest regression was used to look for protective factors and risk factors of low bone density;The correlation between serum sclerostin level and bone mineral density was analyzed,and ROC curve was used to explore whether serum sclerostin level could be used to predict low level bone mineral density.Results The median serum sclerostin concentration of 62 patients was 166.74(105.87,311.90)pmol/L.Spearman correlation analysis showed that serum sclerostin levels were positively correlated with BMI,serum calcium and 25(OH)VitD levels(r= 0.327,0.323,0.257,P= 0.010,0.049,0.044),while negatively correlated with lg[iPTH],spKt/v,triglyceride(TG),low density lipoprotein cholesterol(LDL-C)(r=-0.254,-0.279,-0.186,-0.314,P=0.046,0.012,0.027,0.031).Serum Sclerostin level was not related with serum phosphorus,alkaline phosphatase(AKP),high density lipoprotein cholesterol(HDL-C)and LDL(P>0.05) .Correlation analysis showed serum sclerostin levels were significantly and positively correlated with BMD(r=0.328,P=0.009).Logistic regression showed that serum sclerostin level was a risk factor for BMD(OR=1.17,95%CI(0.928~1.474);P=0.008).The ROC curve was established,and the area under the curve of serum sclerostin diagnosis was 87.9%.Conclusion Serum sclerostin levels are positively correlated with bone mineral density.And serum sclerostin levels may become a marker to predict the prognosis in MHD patients.